US Pandemic Relief Package Delivers OTC Industry Regulatory Wishes, Supplement Business Hopes
It’s unlikely any industry stakeholder or FDA official expected a bill providing emergency economic relief to consumers, industries and health care services and facilities in response to a pandemic, including extensive support opportunities for small businesses, would be the vehicle that delivers on both of the industry’s congressional wishes. The supplement industry also looks for help in CARES Act.
You may also be interested in...
Reps. Brendan Boyle and Darin LaHood introduce Dietary Supplement Tax Fairness Ac to amend Internal Revenue Code to include some supplement products as qualified medical expenses.
Federal law requiring agencies to weigh and document potential environmental impacts of major regulatory actions does not dictate what happens next. Neither does it endow federal agencies with authorities beyond their statutory purviews, FDA/CDER leadership says.
FDA publishes second notice on FY2021 rates for OTC monograph drug user fee program. With fewer firms paying, those still subject to facility fees will pay more so the total collected matches amount Congress authorized agency to collect, nearly $23.3m.